These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10444027)

  • 1. Novel self-sampling culture method to monitor excretion of live, oral Shigella flexneri 2a vaccine SC602 during a community-based phase 1 trial.
    Teska JD; Coster T; Byrne WR; Colbert JR; Taylor D; Venkatesan M; Hale TL
    J Lab Clin Med; 1999 Aug; 134(2):141-6. PubMed ID: 10444027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.
    Katz DE; Coster TS; Wolf MK; Trespalacios FC; Cohen D; Robins G; Hartman AB; Venkatesan MM; Taylor DN; Hale TL
    Infect Immun; 2004 Feb; 72(2):923-30. PubMed ID: 14742537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
    Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH
    Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
    Coster TS; Hoge CW; VanDeVerg LL; Hartman AB; Oaks EV; Venkatesan MM; Cohen D; Robin G; Fontaine-Thompson A; Sansonetti PJ; Hale TL
    Infect Immun; 1999 Jul; 67(7):3437-43. PubMed ID: 10377124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
    Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
    Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
    Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602.
    Bârzu S; Arondel J; Guillot S; Sansonetti PJ; Phalipon A
    Infect Immun; 1998 Jan; 66(1):77-82. PubMed ID: 9423842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes.
    Kärnell A; Sweiha H; Lindberg AA
    Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.
    Li A; Kärnell A; Huan PT; Cam PD; Minh NB; Trâm LN; Quy NP; Trach DD; Karlsson K; Lindberg G
    Vaccine; 1993; 11(2):180-9. PubMed ID: 8438616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose.
    Mel DM; Arsic BL; Radovanovic ML; Litvinjenko SA
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):109-14. PubMed ID: 4613128
    [No Abstract]   [Full Text] [Related]  

  • 11. An outbreak of Sonne shigellosis in a population receiving oral attenuated shigella vaccines.
    Levine MM; Rice PA; Gangarosa EJ; Morris GK; Snyder MJ; Formal SB; Wells JG; Gemski P; Hammond J
    Am J Epidemiol; 1974 Jan; 99(1):30-6. PubMed ID: 4590191
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.
    Formal SB; Hale TL; Kapfer C; Cogan JP; Snoy PJ; Chung R; Wingfield ME; Elisberg BL; Baron LS
    Infect Immun; 1984 Nov; 46(2):465-9. PubMed ID: 6389344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An auxotrophic live oral Shigella flexneri vaccine: development and testing.
    Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP; Cam PD; Trach DD; Lindberg AA
    Rev Infect Dis; 1991; 13 Suppl 4():S357-61. PubMed ID: 2047663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.
    Li A; Pál T; Forsum U; Lindberg AA
    Vaccine; 1992; 10(6):395-404. PubMed ID: 1598788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.
    Simon JK; Wahid R; Maciel M; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Vaccine; 2009 Jan; 27(4):565-72. PubMed ID: 19022324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers.
    Kärnell A; Li A; Zhao CR; Karlsson K; Nguyen BM; Lindberg AA
    Vaccine; 1995 Jan; 13(1):88-99. PubMed ID: 7762285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.
    Kotloff KL; Nataro JP; Losonsky GA; Wasserman SS; Hale TL; Taylor DN; Sadoff JC; Levine MM
    Vaccine; 1995 Nov; 13(16):1488-94. PubMed ID: 8578831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier.
    Barzu S; Fontaine A; Sansonetti P; Phalipon A
    Infect Immun; 1996 Apr; 64(4):1190-6. PubMed ID: 8606077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral shigella vaccines.
    Hale TL; Formal SB
    Curr Top Microbiol Immunol; 1989; 146():205-11. PubMed ID: 2659269
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.
    DuPont HL; Hornick RB; Snyder MJ; Libonati JP; Formal SB; Gangarosa EJ
    J Infect Dis; 1972 Jan; 125(1):12-6. PubMed ID: 4550416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.